BACKGROUND AND PURPOSE: Substance P (SP) and calcitonin gene-related peptide (CGRP) released from capsaicin-sensitive sensory nerves induce local neurogenic inflammation; somatostatin exerts systemic anti-inflammatory actions presumably via sst4/sst1 receptors. This study investigates the effects of a high affinity, sst4-selective, synthetic agonist, J-2156, on sensory neuropeptide release in vitro and inflammatory processes in vivo. EXPERIMENTAL APPROACH: Electrically-induced SP, CGRP and somatostatin release from isolated rat tracheae was measured with radioimmunoassay. Mustard oil-induced neurogenic inflammation in rat hindpaw skin was determined by Evans blue leakage and in the mouse ear with micrometry. Dextran-, carrageenan- or bradykinin-induced non-neurogenic inflammation was examined with plethysmometry or Evans blue, respectively. Adjuvant-induced chronic arthritis was assessed by plethysmometry and histological scoring. Granulocyte accumulation was determined with myeloperoxidase assay and IL-1beta with ELISA. KEY RESULTS: J-2156 (10-2000 nM) diminished electrically-evoked neuropeptide release in a concentration-dependent manner. EC50 for the inhibition of substance P, CGRP and somatostatin release were 11.6 nM, 14.3 nM and 110.7 nM, respectively. J-2156 (1-100 microg kg(-1) i.p.) significantly, but not dose-dependently, inhibited neurogenic and non-neurogenic acute inflammatory processes and adjuvant-induced chronic oedema and arthritic changes. Endotoxin-evoked myeloperoxidase activity and IL-1beta production in the lung, but not IL-1beta- or zymosan-induced leukocyte accumulation in the skin were significantly diminished by J-2156. CONCLUSIONS AND IMPLICATIONS: J-2156 acting on sst4 receptors inhibits neuropeptide release, vascular components of acute inflammatory processes, endotoxin-induced granulocyte accumulation and IL-1beta synthesis in the lung and synovial and inflammatory cells in chronic arthritis. Therefore it might be a promising lead for the development of novel anti-inflammatory drugs.
BACKGROUND AND PURPOSE: Substance P (SP) and calcitonin gene-related peptide (CGRP) released from capsaicin-sensitive sensory nerves induce local neurogenic inflammation; somatostatin exerts systemic anti-inflammatory actions presumably via sst4/sst1 receptors. This study investigates the effects of a high affinity, sst4-selective, synthetic agonist, J-2156, on sensory neuropeptide release in vitro and inflammatory processes in vivo. EXPERIMENTAL APPROACH: Electrically-induced SP, CGRP and somatostatin release from isolated rat tracheae was measured with radioimmunoassay. Mustard oil-induced neurogenic inflammation in rat hindpaw skin was determined by Evans blue leakage and in the mouse ear with micrometry. Dextran-, carrageenan- or bradykinin-induced non-neurogenic inflammation was examined with plethysmometry or Evans blue, respectively. Adjuvant-induced chronic arthritis was assessed by plethysmometry and histological scoring. Granulocyte accumulation was determined with myeloperoxidase assay and IL-1beta with ELISA. KEY RESULTS:J-2156 (10-2000 nM) diminished electrically-evoked neuropeptide release in a concentration-dependent manner. EC50 for the inhibition of substance P, CGRP and somatostatin release were 11.6 nM, 14.3 nM and 110.7 nM, respectively. J-2156 (1-100 microg kg(-1) i.p.) significantly, but not dose-dependently, inhibited neurogenic and non-neurogenic acute inflammatory processes and adjuvant-induced chronic oedema and arthritic changes. Endotoxin-evoked myeloperoxidase activity and IL-1beta production in the lung, but not IL-1beta- or zymosan-induced leukocyte accumulation in the skin were significantly diminished by J-2156. CONCLUSIONS AND IMPLICATIONS: J-2156 acting on sst4 receptors inhibits neuropeptide release, vascular components of acute inflammatory processes, endotoxin-induced granulocyte accumulation and IL-1beta synthesis in the lung and synovial and inflammatory cells in chronic arthritis. Therefore it might be a promising lead for the development of novel anti-inflammatory drugs.
Authors: Tatsuya Okamoto; Kishorchandra Gohil; Erik I Finkelstein; Peter Bove; Takaaki Akaike; Albert van der Vliet Journal: Am J Physiol Lung Cell Mol Physiol Date: 2003-09-12 Impact factor: 5.464
Authors: Zsuzsanna Helyes; Arpád Szabó; József Németh; Balázs Jakab; Erika Pintér; Agnes Bánvölgyi; László Kereskai; György Kéri; János Szolcsányi Journal: Arthritis Rheum Date: 2004-05
Authors: K-J Bär; U Schurigt; A Scholze; G Segond Von Banchet; N Stopfel; R Bräuer; K-J Halbhuber; H-G Schaible Journal: Neuroscience Date: 2004 Impact factor: 3.590
Authors: Zsuzsanna Helyes; Erika Pintér; Katalin Sándor; Krisztián Elekes; Agnes Bánvölgyi; Dániel Keszthelyi; Eva Szoke; Dániel M Tóth; Zoltán Sándor; László Kereskai; Gábor Pozsgai; Jeremy P Allen; Piers C Emson; Adrienn Markovics; János Szolcsányi Journal: Proc Natl Acad Sci U S A Date: 2009-07-21 Impact factor: 11.205
Authors: Zoltán Varecza; Krisztián Elekes; Terézia László; Anikó Perkecz; Erika Pintér; Zoltán Sándor; János Szolcsányi; Dániel Keszthelyi; Arpád Szabó; Katalin Sándor; Tamás F Molnár; Zalán Szántó; Judit E Pongrácz; Zsuzsanna Helyes Journal: J Histochem Cytochem Date: 2009-08-17 Impact factor: 2.479
Authors: Eva Borbély; Zsófia Hajna; Katalin Sándor; László Kereskai; István Tóth; Erika Pintér; Péter Nagy; János Szolcsányi; John Quinn; Andreas Zimmer; James Stewart; Christopher Paige; Alexandra Berger; Zsuzsanna Helyes Journal: PLoS One Date: 2013-04-23 Impact factor: 3.240
Authors: István Z Bátai; Ádám Horváth; Erika Pintér; Zsuzsanna Helyes; Gábor Pozsgai Journal: Front Endocrinol (Lausanne) Date: 2018-02-27 Impact factor: 5.555
Authors: Joseph Schober; Jahnavi Polina; Field Walters; Nathan Scott; Eric Lodholz; Albert Crider; Karin Sandoval; Ken Witt Journal: PLoS One Date: 2021-07-08 Impact factor: 3.240